54963-70-1

Basic information

• Product Name: 4-N-NONYLBENZOYL CHLORIDE
• Synonyms: 4-n-Nonylbenzoylchloride,98%;4-nonylBenzoyl chloride;4-N-NONYLBENZOYL CHLORIDE;P-NONYLBENZOYL CHLORIDE
• CAS NO: 54963-70-1
• Molecular Formula: C₁₆H₂₃ClO
• Molecular Weight: 266.81
• Mol File: 54963-70-1.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 353°C at 760 mmHg
• Flash Point: 167.6°C
• Appearance: /
• Density: 1.009g/cm³
• Vapor Pressure: 3.68E-05mmHg at 25°C
• Refractive Index: 1.505
• Sensitive: Moisture Sensitive
• CAS DataBase Reference: 4-N-NONYLBENZOYL CHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-N-NONYLBENZOYL CHLORIDE(54963-70-1)
• EPA Substance Registry System: 4-N-NONYLBENZOYL CHLORIDE(54963-70-1)

Safety Data

• Statements: 20/21/22-34-36/37
• Safety Statements: 26-27-28-36/37/39
• RIDADR: 1759
• HazardClass: 8
• PackingGroup: II
• Hazardous Substances Data: 54963-70-1(Hazardous Substances Data)

Usage

General Description

4-N-Nonylbenzoyl chloride is a chemical compound with the formula C16H25ClO. It is a derivative of benzoyl chloride, with a nonyl group attached at the 4-position of the benzene ring. 4-N-NONYLBENZOYL CHLORIDE is commonly used in organic synthesis as a reagent for the preparation of various organic compounds, such as esters, amides, and ketones. It can also be employed as a building block in the production of pharmaceuticals, agrochemicals, and other specialty chemicals. 4-N-Nonylbenzoyl chloride is considered to be a hazardous chemical and must be handled and stored with proper safety precautions.

InChI:InChI=1/C16H23ClO/c1-2-3-4-5-6-7-8-9-14-10-12-15(13-11-14)16(17)18/h10-13H,2-9H2,1H3

Upstream product

• 844656-92-4 4-nonylbenzoic acid methyl ester 
• 827028-03-5 methyl 4-(non-1-yn-1-yl)benzoate 
• 619-44-3 methyl 4-iodobenzoate 
• 619-58-9 4-iodobenzoic acid 
• 38289-46-2 4-n-Nonylbenzoic acid 
• 79-37-8 oxalyl dichloride 
• 1081-77-2 n-nonylbenzene 

Downstream Products

• 70972-98-4 4-(n-nonyl)benzaldehyde 
• 748733-78-0 4-nonylbenzamide 
• 1537168-38-9 2-{1-[4-methyl-2-(4-nonylphenyl)thiazol-5-yl]ethylidene}hydrazinecarboximidamide 
• 1537168-63-0 1-[4-methyl-2-(4-nonylphenyl)thiazol-5-yl]ethanone 
• 1537168-51-6 4-nonylthiobenzamide 
• 1227623-87-1 N-(2-azidoethyl)-4-nonylbenzamide 
• 786702-97-4 N-methoxy-N-methyl-4-nonyl-benzamide 
• 61518-86-3 4-Nonyl-thiobenzoic acid S-(4-pentyl-phenyl) ester 

Relevant articles and documents

Nonpeptidic, Polo-Box Domain-Targeted Inhibitors of PLK1 Block Kinase Activity, Induce Its Degradation and Target-Resistant Cells

PLK1, polo-like kinase 1, is a central player regulating mitosis. Inhibition of the subcellular localization and kinase activity of PLK1 through the PBD, polo-box domain, is a viable alternative to ATP-competitive inhibitors, for which the development of resistance and inhibition of related PLK family members are concerns. We describe novel nonpeptidic PBD-binding inhibitors, termed abbapolins, identified through successful application of the REPLACE strategy and demonstrate their potent antiproliferative activity in prostate tumors and other cell lines. Furthermore, abbapolins show PLK1-specific binding and inhibitory activity, as measured by a cellular thermal shift assay and an ability to block phosphorylation of TCTP, a validated target of PLK1-mediated kinase activity. Additional evidence for engagement of PLK1 was obtained through the unique observation that abbapolins induce PLK1 degradation in a manner that closely matches antiproliferative activity. Moreover, abbapolins demonstrate antiproliferative activity in cells that are dramatically resistant to ATP-competitive PLK1 inhibitors.

Discovery and characterization of potent thiazoles versus methicillin- and vancomycin-resistant Staphylococcus aureus

Methicillin- and vancomycin-resistant Staphylococcus aureus (MRSA and VRSA) infections are growing global health concerns. Structure-activity relationships of phenylthiazoles as a new antimicrobial class have been addressed. We present 10 thiazole derivatives that exhibit strong activity against 18 clinical strains of MRSA and VRSA with acceptable PK profile. Three derivatives revealed an advantage over vancomycin by rapidly eliminating MRSA growth within 6 h, and no derivatives are toxic to HeLa cells at 11 μg/mL.

Preparation of 4-alkyl-and 4-halobenzoyl chlorides: 4-Pentylbenzoyl chloride

-